Primary sclerosing cholangitis (PSC) is a condition causing long-term inflammation and scarring (fibrosis) of bile ducts in the liver. These ducts are tubes that allow the liquid (bile) produced by the liver to pass through the intestine allowing fat digestion. This disease predominantly affects men between the age of 25 and 40 years. The damage to the ducts causes accumulation of bile acids, essential components of bile to build up in the liver leading to liver tissue damage, portal hypertension (high blood pressure in the vessels connecting the liver and the gut), and liver failure, and may increase the risk of liver cancer.

Requirement of providing affordable treatment, owing to high costs associated with liver transplantation coupled with increasing risk factors resulting in the development of serious disorders are major factors that are expected to increase the adoption of PSC drugs, in turn favoring market growth in the near future.

In 2018, the global Primary Sclerosing Cholangitis market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Primary Sclerosing Cholangitis status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Primary Sclerosing Cholangitis development in United States, Europe and China.

The key players covered in this study
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Shire Plc.
NGM Biopharmaceuticals, Inc.
Dr. Falk Pharma GmbH
Allergan Plc.
Conatus Pharmaceuticals, Inc.
Durect Corporation
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceuticals Ltd.

Market segment by Type, the product can be split into
Type I
Type II

Market segment by Application, split into
Hospital
Clinics
Other

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Primary Sclerosing Cholangitis status, future forecast, growth opportunity, key market and key players.
To present the Primary Sclerosing Cholangitis development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Primary Sclerosing Cholangitis are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
1.5 Market by Application
   - 1.5.1 Global Primary Sclerosing Cholangitis Market Share by Application (2014-2025)
   - 1.5.2 Hospital
   - 1.5.3 Clinics
   - 1.5.4 Other
   - 1.6 Study Objectives
   - 1.7 Years Considered

2 Global Growth Trends
   - 2.1 Primary Sclerosing Cholangitis Market Size
   - 2.2 Primary Sclerosing Cholangitis Growth Trends by Regions
     - 2.2.1 Primary Sclerosing Cholangitis Market Size by Regions (2014-2025)
     - 2.2.2 Primary Sclerosing Cholangitis Market Share by Regions (2014-2019)
   - 2.3 Industry Trends
     - 2.3.1 Market Top Trends
     - 2.3.2 Market Drivers
     - 2.3.3 Market Opportunities

3 Market Share by Key Players
   - 3.1 Primary Sclerosing Cholangitis Market Size by Manufacturers
     - 3.1.1 Global Primary Sclerosing Cholangitis Revenue by Manufacturers (2014-2019)
     - 3.1.2 Global Primary Sclerosing Cholangitis Revenue Market Share by Manufacturers (2014-2019)
     - 3.1.3 Global Primary Sclerosing Cholangitis Market Concentration Ratio (CR5 and HHI)
   - 3.2 Primary Sclerosing Cholangitis Key Players Head office and Area Served
   - 3.3 Key Players Primary Sclerosing Cholangitis Product/Solution/Service
   - 3.4 Date of Enter into Primary Sclerosing Cholangitis Market
   - 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
   - 4.1 Global Primary Sclerosing Cholangitis Market Size by Type (2014-2019)
   - 4.2 Global Primary Sclerosing Cholangitis Market Size by Application (2014-2019)

5 United States
   - 5.2 Primary Sclerosing Cholangitis Key Players in United States
   - 5.3 United States Primary Sclerosing Cholangitis Market Size by Type
   - 5.4 United States Primary Sclerosing Cholangitis Market Size by Application

6 Europe
   - 6.1 Europe Primary Sclerosing Cholangitis Market Size (2014-2019)
   - 6.2 Primary Sclerosing Cholangitis Key Players in Europe
   - 6.3 Europe Primary Sclerosing Cholangitis Market Size by Type
   - 6.4 Europe Primary Sclerosing Cholangitis Market Size by Application

7 China
   - 7.2 Primary Sclerosing Cholangitis Key Players in China
   - 7.3 China Primary Sclerosing Cholangitis Market Size by Type
   - 7.4 China Primary Sclerosing Cholangitis Market Size by Application

8 Japan
   - 8.2 Primary Sclerosing Cholangitis Key Players in Japan
   - 8.3 Japan Primary Sclerosing Cholangitis Market Size by Type
   - 8.4 Japan Primary Sclerosing Cholangitis Market Size by Application

9 Southeast Asia
   - 9.1 Southeast Asia Primary Sclerosing Cholangitis Market Size (2014-2019)
   - 9.2 Primary Sclerosing Cholangitis Key Players in Southeast Asia
   - 9.3 Southeast Asia Primary Sclerosing Cholangitis Market Size by Type
   - 9.4 Southeast Asia Primary Sclerosing Cholangitis Market Size by Application

10 India
    - 10.1 India Primary Sclerosing Cholangitis Market Size (2014-2019)
    - 10.2 Primary Sclerosing Cholangitis Key Players in India
    - 10.3 India Primary Sclerosing Cholangitis Market Size by Type
    - 10.4 India Primary Sclerosing Cholangitis Market Size by Application

11 Central & South America
    - 11.1 Central & South America Primary Sclerosing Cholangitis Market Size (2014-2019)
    - 11.2 Primary Sclerosing Cholangitis Key Players in Central & South America
    - 11.3 Central & South America Primary Sclerosing Cholangitis Market Size by Type
    - 11.4 Central & South America Primary Sclerosing Cholangitis Market Size by Application

12 International Players Profiles
   - 12.1 Acorda Therapeutics, Inc.
     - 12.1.1 Acorda Therapeutics, Inc. Company Details
     - 12.1.2 Company Description and Business Overview
     - 12.1.3 Primary Sclerosing Cholangitis Introduction
     - 12.1.4 Acorda Therapeutics, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
     - 12.1.5 Acorda Therapeutics, Inc. Recent Development
   - 12.2 Gilead Sciences, Inc.
     - 12.2.1 Gilead Sciences, Inc. Company Details
     - 12.2.2 Company Description and Business Overview
     - 12.2.3 Primary Sclerosing Cholangitis Introduction
     - 12.2.4 Gilead Sciences, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
     - 12.2.5 Gilead Sciences, Inc. Recent Development
12.3 Intercept Pharmaceuticals, Inc.
- 12.3.1 Intercept Pharmaceuticals, Inc. Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Primary Sclerosing Cholangitis Introduction
- 12.3.5 Intercept Pharmaceuticals, Inc. Recent Development

12.4 Shire Plc.
- 12.4.1 Shire Plc. Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Primary Sclerosing Cholangitis Introduction
- 12.4.4 Shire Plc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
- 12.4.5 Shire Plc. Recent Development

12.5 NGM Biopharmaceuticals, Inc.
- 12.5.1 NGM Biopharmaceuticals, Inc. Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Primary Sclerosing Cholangitis Introduction
- 12.5.4 NGM Biopharmaceuticals, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
- 12.5.5 NGM Biopharmaceuticals, Inc. Recent Development

12.6 Dr. Falk Pharma GmbH
- 12.6.1 Dr. Falk Pharma GmbH Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Primary Sclerosing Cholangitis Introduction
- 12.6.4 Dr. Falk Pharma GmbH Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
- 12.6.5 Dr. Falk Pharma GmbH Recent Development

12.7 Allergan Plc.
- 12.7.1 Allergan Plc. Company Details
- 12.7.2 Company Description and Business Overview
- 12.7.3 Primary Sclerosing Cholangitis Introduction
- 12.7.4 Allergan Plc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
- 12.7.5 Allergan Plc. Recent Development

12.8 Conatus Pharmaceuticals, Inc.
- 12.8.1 Conatus Pharmaceuticals, Inc. Company Details
- 12.8.2 Company Description and Business Overview
- 12.8.3 Primary Sclerosing Cholangitis Introduction
- 12.8.4 Conatus Pharmaceuticals, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
- 12.8.5 Conatus Pharmaceuticals, Inc. Recent Development

12.9 Durect Corporation
- 12.9.1 Durect Corporation Company Details
- 12.9.2 Company Description and Business Overview
- 12.9.3 Primary Sclerosing Cholangitis Introduction
- 12.9.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
- 12.9.5 Durect Corporation Recent Development

12.10 Sirnaomics, Inc.
- 12.10.1 Sirnaomics, Inc. Company Details
- 12.10.2 Company Description and Business Overview
- 12.10.3 Primary Sclerosing Cholangitis Introduction
- 12.10.4 Sirnaomics, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
- 12.10.5 Sirnaomics, Inc. Recent Development

12.11 Shenzhen HighTide Biopharmaceuticals Ltd.

13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Regions
- 13.2 United States
- 13.3 Europe
- 13.4 China
- 13.5 Japan
- 13.6 Southeast Asia
- 13.7 India
- 13.8 Central & South America
- 13.9 Market Size Forecast by Product (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
- 15.1 Research Methodology
  - 15.1.1 Methodology/Research Approach
    - 15.1.1.1 Research Programs/Design
    - 15.1.1.2 Market Size Estimation
    - 15.1.1.3 Market Breakdown and Data Triangulation
  - 15.1.2 Data Source
    - 15.1.2.1 Secondary Sources
    - 15.1.2.2 Primary Sources
- 15.2 Disclaimer